A Trifecta of Troubles: How Privacy, Insider Sales, and High Rates Are Undermining Palantir's Record Quarter

Strong Q1 results and raised guidance fail to lift Palantir stock amid NHS data privacy row, $435M insider sales, and macro pressure on high-multiple growth names.

Palantir Technologies is delivering the kind of numbers that usually send a stock rocketing. First-quarter revenue surged 85% to $1.633 billion, US commercial business more than doubled, and the order backlog swelled to $11.8 billion. Management raised its full-year forecast to $7.66 billion. Yet the share price has lost more than a fifth of its value since January, sliding to 110.82 euros on Thursday after closing at 111.12 euros the day before — perilously close to the 52-week low of roughly 105 euros.

The disconnect between operating performance and market sentiment is as wide as it has been in months, and it stems from three distinct but converging headwinds: a deepening data privacy row with the UK’s National Health Service, a torrent of insider stock sales, and a macro backdrop that increasingly penalizes richly valued software names.

The NHS contract — a 330-million-pound deal awarded in 2023 for Palantir’s Federated Data Platform — has turned into a political sore point. An internal briefing warned that a change in access policy could erode public trust, because a new administrative route now permits Palantir employees to view identifiable patient data. The company insists it remains a data processor under UK law, with customers retaining control, and that any misuse would be both illegal and technically impossible thanks to granular controls under NHS oversight. Still, several parliamentarians have voiced unease over Palantir’s ties to the US military, and Greater Manchester — home to 2.8 million people — remains the only NHS region in England to boycott the platform entirely, citing insufficient evidence of its benefits. The first extension option falls due in 2026, and the initial contract expires in March 2027, making every privacy skirmish a potential threat to renewal.

Compounding the political risk, company insiders have been cashing out. Over the past three months, Palantir executives and directors sold shares worth $435 million. While insider selling is not unusual after a period of strong price appreciation — the stock hit a record high last year — the sheer size of the disposals has caught the attention of market watchers, especially at a time when the broader growth-stock rally has faltered.

That broader rally has been torpedoed by sticky US inflation, which has dashed hopes for imminent interest-rate cuts. The yield on the benchmark 10-year Treasury note climbed to 4.49%, pressuring high-multiple equities disproportionately. Palantir trades at roughly 93 times expected earnings, a level that leaves little room for error even before adding a political discount. By revenue, the multiple is a more forgiving 42 times 2026 sales, but that still embeds an assumption of flawless execution.

Analysts are split on where the stock goes from here. The Wall Street consensus sits at $183.73 per share, with Argus calling for $190. Morningstar sets a fair value of $153, warning that the competitive landscape is getting crowded. Anthropic and OpenAI are both building out their own enterprise integration capabilities, and falling costs for AI inference could lower the very barriers that have protected Palantir’s moat. Next quarter’s results, with management targeting around $1.8 billion in revenue, will provide the next real test of whether the growth trajectory can withstand the mounting noise.

For now, Palantir’s story is one of stark contrasts: a company that just posted its best-ever quarter but whose stock is within striking distance of a 52-week low, weighed down by a privacy dispute, insider exits, and interest rates that refuse to cooperate. The next act will depend on whether the UK government renews its NHS trust — or whether the data storm turns into a contract casualty.